French pharmaceutical company Sanofi, first messenger RNA (mRNA) based new type corona virus (Covid-19) announced positive interim results from an early clinical trial of a vaccine candidate.
Sanofi announced that the Phase 1/2 study produced coronavirus-neutralizing antibodies in 91 percent to 100 percent of study participants two weeks after a second injection.
However, the company added that no safety concerns were observed and side effects were comparable to those of other messenger RNA or mRNA Covid-19 vaccines (Pfizer/BioNTech and Moderna).
Sanofi stated that more data from the study will be made available at a later date.
“WE HAVE A HOLY MRNA VACCINE”
“Today we have a promising mRNA vaccine that we are taking to the next level in development against Covid-19 and other diseases, including influenza,” said Jean-Francois Toussaint, Global Head of Research and Development at Sanofi Pasteur.
On the other hand, Toussaint said that the studies of a separate corona virus vaccine developed in partnership with GlaxoSmithKline continue in the Phase 3 phase.
VACCINE DEVELOPED WITH GSK IS IN PHASE 3
Healthcare companies Sanofi and GSK announced last May that they had launched global Phase 3 clinical trials to evaluate the safety, efficacy, and immunogenicity (ability to elicit an immune response) of protein-based adjuvanted recombinant COVID-19 vaccine candidates.
According to the statement made by Sanofi and GSK, the Phase 3 study, which will be conducted in a randomized, double-blind, placebo-controlled manner, is carried out with the participation of more than 35 thousand volunteers aged 18 and over from various countries of the world, including the USA, Asia, Africa and Latin America. .
FRANCE CUMGURBAŞKANI MACRON’S Egg Salt